Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
- 11 August 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Diabetes & Endocrinology
- Vol. 3 (9), 697-703
- https://doi.org/10.1016/s2213-8587(15)00233-8
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2013
- Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysisCardiovascular Diabetology, 2013
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitusNature Reviews Endocrinology, 2012
- The effect of glucagon-like peptide 1 on cardiovascular riskNature Reviews Cardiology, 2012
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programmeCardiovascular Diabetology, 2012
- Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studiesDiabetes and Vascular Disease Research, 2011
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetesCardiovascular Diabetology, 2011
- A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 DiabetesPostgraduate Medicine, 2010
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- High heart rate: a cardiovascular risk factor?European Heart Journal, 2006